- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 684-698 of
973 results
2549 Exhibit: EX2549 Email Notice of Electronic Filing Corresponding to In re Ozem...
Document
IPR2023-00724, No. 2549 Exhibit - EX2549 Email Notice of Electronic Filing Corresponding to In re Ozempic Semaglutide Patent Litigation, No 122 cv 03038 CFC Dkt 334 (P.T.A.B. Jul. 31, 2024...
|
|
Cite Document
2005 Exhibit: EX2005 Knight, A, “Systematic Reviews of Animal Experiments Demo...
Document
IPR2023-00724, No. 2005 Exhibit - EX2005 Knight, A, “Systematic Reviews of Animal Experiments Demonstrate Poor Contributions Toward Human Healthcare,” Reviews on Recent Clinical Trial...
|
|
Cite Document
2535 Exhibit: EX2535 Declaration of Jenny C Wu
Document
IPR2023-00724, No. 2535 Exhibit - EX2535 Declaration of Jenny C Wu (P.T.A.B. Apr. 10, 2024)
|
|
Cite Document
2079 Exhibit: EX2079 United States Patent and Trademark Office, Consolidated Tr...
Document
IPR2023-00724, No. 2079 Exhibit - EX2079 United States Patent and Trademark Office, Consolidated Trial Practice Guide, Appendix B Default Protective Order November 2019 (P.T.A.B. Jan. ...
|
|
Cite Document
2016 Exhibit: EX2016 Mehdi, S, et al, “Glucagon like peptide 1 a multi faceted anti i...
Document
IPR2023-00724, No. 2016 Exhibit - EX2016 Mehdi, S, et al, “Glucagon like peptide 1 a multi faceted anti inflammatory agent,” Frontiers in Immunology, Vol 14 2023 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2514 Exhibit: EX2514 Novo Nordisk, Financial report for the period 1 January 2023...
Document
IPR2023-00724, No. 2514 Exhibit - EX2514 Novo Nordisk, Financial report for the period 1 January 2023 to 31 March 2023 May 4, 2023 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2076 Exhibit: EX2076 Ozempic® Prescribing Information March 2022
Document
IPR2023-00724, No. 2076 Exhibit - EX2076 Ozempic® Prescribing Information March 2022 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2495 Exhibit: EX2495 Novo Nordisk, Financial report for the period 1 January 2018...
Document
IPR2023-00724, No. 2495 Exhibit - EX2495 Novo Nordisk, Financial report for the period 1 January 2018 to 30 June 2018 Aug 8, 2018 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2104 Exhibit: EX2104 Maskery, MP, et al, Glucagon like peptide 1 receptor agonist...
Document
IPR2023-00724, No. 2104 Exhibit - EX2104 Maskery, MP, et al, Glucagon like peptide 1 receptor agonists as neuroprotective agents for ischemic stroke a systematic scoping review, J Cereb Bl...
|
|
Cite Document
2603 Exhibit: EX2603 S Coca et al, Role of Intensive Glucose Control in Developme...
Document
IPR2023-00724, No. 2603 Exhibit - EX2603 S Coca et al, Role of Intensive Glucose Control in Development of Re nal End Points in Type 2 Diabetes Mellitus, Arch Intern Med Vol 172 2012 Marke...
|
|
Cite Document
2366 Exhibit: EX2366 Cleveland Clinic, “Biguanides,” httpsmyclevelandclinicorghea...
Document
IPR2023-00724, No. 2366-2 Exhibit - EX2366 Cleveland Clinic, “Biguanides,” httpsmyclevelandclinicorghealthtreatments25004 biguanides, last reviewed May 22, 2023 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2099 Exhibit: EX2099 Kleindorfer, DO, et al, Guideline for the Prevention of Stroke...
Document
IPR2023-00724, No. 2099 Exhibit - EX2099 Kleindorfer, DO, et al, Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack, Stroke, 52e364–e467 2021 (P.T....
|
|
Cite Document
2444 Exhibit: EX2444 US Food Drug Administration, DrugsFDA, Invokamet® XR
Document
IPR2023-00724, No. 2444 Exhibit - EX2444 US Food Drug Administration, DrugsFDA, Invokamet® XR (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2372 Exhibit: EX2372 Eggleton, JS and Jialal, I, Thiazolidinediones, StatPearls Inte...
Document
IPR2023-00724, No. 2372 Exhibit - EX2372 Eggleton, JS and Jialal, I, Thiazolidinediones, StatPearls Internet, available at httpswwwncbinlmnihgovbooksNBK551656, last updated Feb 20, 2023...
|
|
Cite Document
2006 Exhibit: EX2006 Arrowsmith, J, “Phase II failures 2008–2010,” Nature Reviews...
Document
IPR2023-00724, No. 2006 Exhibit - EX2006 Arrowsmith, J, “Phase II failures 2008–2010,” Nature Reviews, Drug Discovery, Vol 10 May 2011 (P.T.A.B. Jul. 6, 2023)
|
|
Cite Document
